Sugi Predict

Sugi Predict / Compounds / SCHEMBL214459

SCHEMBL214459

SCHEMBL214459

CCOC(=O)C(=COC)C(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 4/20 0.56
▸ GLO1 Q04760 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ LMNA P02545 5/20 0.43
▸ MAPT P10636 5/20 0.43
▸ PLIN1 O60240 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ PLIN5 Q00G26 1/20 0.43
▸ ABHD5 Q8WTS1 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ S1PR4 O95977 1/20 0.43
▸ S1PR1 P21453 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ DHODH Q02127 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23394794 0.94 NPSR1 (0.50) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL296438 0.89 NPSR1 (0.50) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL28285733 0.89 GLO1 (0.67) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL9048705 0.89 GLO1 (0.67) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL9048698 0.89 GLO1 (0.67) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL11655592 0.87 NPSR1 (0.48) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL11655595 0.87 NPSR1 (0.48) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL18936341 0.84 NPSR1 (0.46) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL11654386 0.84 NPSR1 (0.46) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6
SCHEMBL11650351 0.84 NPSR1 (0.46) NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106543312-B A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2019-06-28 — — CN claimed
CN-106543310-B A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2019-06-28 — — CN claimed
CN-106543313-B A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2019-06-28 — — CN claimed
CN-106543314-B The application of catalyst containing ether ester and the catalyst and ether ester in olefin polymerization 中国石油化工股份有限公司 2019-02-19 — — CN claimed
CN-105622800-B A kind of catalytic component and its catalyst system for olefinic polyreaction 中国石油化工股份有限公司 2017-12-19 — — CN claimed
CN-106543312-A A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2017-03-29 — — CN claimed
CN-106543313-A A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2017-03-29 — — CN claimed
CN-106543314-A The application of catalyst containing ether ester and the catalyst and ether ester in olefinic polyreaction 中国石油化工股份有限公司 2017-03-29 — — CN claimed
CN-106543310-A A kind of olefin polymerization catalyst system and its application 中国石油化工股份有限公司 2017-03-29 — — CN claimed
CN-118063648-A Solid catalyst component for propylene polymerization and propylene polymerization catalyst system 中国石油天然气股份有限公司 2024-05-24 — — CN disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 — — EP disclosed
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-02 — — US disclosed
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-02 — — US disclosed
CN-117083269-A Uracil derivatives as TRPA1 inhibitors 勃林格殷格翰国际有限公司 2023-11-17 — — CN disclosed
US-6162944-A Process for production of N-cyclopropylanilines and intermediates therefor IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2000-12-19 — — US disclosed
EP-1031555-A1 N-CYCLOPROPYL-2-DIFLUOROMETHOXY-3-HALOGENOANILINES AND INTERMEDIATES FOR THE PREPARATION THEREOF IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-08-30 — — EP disclosed
EP-0990639-A1 PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-04-05 — — EP disclosed
EP-0332033-A2 N-cyclopropyl anilines and their use in processes for the synthesis of 1-cyclopropyl-quinolone-carboxylic acids and their derivatives BAYER AG (DE) 1989-09-13 — — EP disclosed
US-4190581-A Novel penicillin derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 1980-02-26 — — US disclosed
US-4104049-A Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858921-B2 Uracil derivatives as TRPA1 inhibitors TRPA1, TRPV1, TRPM6 NPSR1 1363/4885GLO1 2848/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.